Fiche centre
Stanford Neuroscience Health Center
Palo Alto — United States
Essais liés12clinical trials
VillePalo Altolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07086521
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ULSC | Myopathies | Phase 1 | NCT07086521 | Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Dihydroergotamine | Migraine | Phase 3 | NCT03901482 | EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine | COMPLETED |
| Vibrotactile Stimulation | Migraine | Non applicable | NCT04069572 | Vibratory Stimulation for the Treatment of Chronic Pain | SUSPENDED |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| bemdaneprocel | Parkinson | Phase 3 | NCT06944522 | exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | RECRUITING |
| KITE-363 | Myasthénie | Phase 1 | NCT07304154 | HERMOSA-2 — Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| zeleciment basivarsen (DYNE-101) | Myopathies | Phase 3 | NCT07486934 | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |
| Casimersen | Myopathies | Phase 3 | NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | TERMINATED |